PHRM — Pharmather Holdings Income Statement
0.000.00%
- CA$10.47m
- CA$9.43m
Annual income statement for Pharmather Holdings, fiscal year end - May 31st, CAD millions except per share, conversion factor applied.
2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.21 | 4.1 | 4.01 | 3.09 | 1.57 |
| Operating Profit | -3.21 | -4.1 | -4.01 | -3.09 | -1.57 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2.89 | -4.24 | -6.42 | -3.12 | -1.53 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.66 | -4.01 | -6.42 | -3.12 | -1.53 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2.66 | -4.01 | -6.42 | -3.12 | -1.53 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.66 | -4.01 | -6.42 | -3.12 | -1.53 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.022 | -0.049 | -0.073 | -0.035 | -0.017 |